The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
The company will acquire ImCheck for €350m.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
